Navigation Links
Biocon Unveils Renal Therapies for Kidney Disorders

India's premier biotechnology firm Biocon Ltd Thursday announced the launch of renal therapy products for treating kidney disorders and reducing// the risk of such disease.

As the leading producer of immuno-suppressants in the subcontinent, the company has set up a nephrology division to market the new products -- Renodapt (Mycophenolate Mofeti), Tacrograf (Tacrolimus), Cyclophil Me (Cyclosporine micro emulsion), Rapacan (Sirolimus) and Erypro (rHuEpo).

"Our renal therapy will enable patients with transplanted kidneys to become immune to any side effects and make them feel compatible with the new organ. Similarly, Erthropoetin (Epo) will increase the hameoglobin level to develop resistance," Bicon chairperson Kiran Mazumdar-Shaw said at a preview of the product.

Prior to the launch, the company has undertaken extensive trials as per the statutory guidelines to demonstrate the safety and efficacy profile of its products. About 300 kidney patients who were administered the drugs responded well to the treatment.

"Our objective is to protect life affected by kidney failures with biotherapeutics and reduce the risk of the disease in future through research and innovative therapies," Shaw said.

Studies have revealed that kidney disease has grown to be a silent epidemic in the 21st century. Every year millions of people across the world are diagnosed with end stage renal disease (ESRD) necessitating kidney treatments.

"The total market size for nephrology products is about Rs.3 billion and is growing by about 20 percent annually. Of these, the market for immuno-suppressants is about Rs.1.25 billion. We are targeting a market share of 20-25 percent in the next three-five years despite aggressive competition from Indian and multinational players in the country," Biocon marketing president Rakesh Bamzai said.

According to "Kidney International", the official journal of the international societ y of nephrology, the incidence of ESRD is likely to be higher in India than in the developed countries, with gloerulonephritis being the most common cause, accounting for one-third of patients, while diabetic nephropathy accounts for about one-fourth of patients.

"In the absence of national registries, no reliable data is available on the incidence and prevalence of ESRD in India. Treatment of ESRD is a low priority for the cash-strapped public hospitals and in the absence of health insurance plans, less than 10 percent of all patients receive any kind of renal replacement therapy," Shaw added.

Source-IANS
'"/>




Related medicine news :

1. Biocon to colloborate for development of Oral peptide drugs for heart diseases.
2. Biocon To Raise Its Investment In Scotland
3. Biocon To Shift Focus On Innovation To Accelerate Growth
4. Kalam Dedicates New Cancer Drug Developed By Biocon
5. Bayer to Market Biocon Insulin in China
6. Biocon Launches Anti-Cancer Drug
7. Biocon to Launch Anti-arthritis Drug
8. Biocon Net Profit Up by 15 Percent for Fiscal Year
9. Study Unveils New Insight To The Madness Of King George III
10. Bush Unveils Latest Blueprint for Handling Bird Flu Pandemic
11. Study Unveils West Nile Virus Immune Evasion, Points to Vaccine Development
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:5/27/2017)... (PRWEB) , ... May 27, 2017 , ... Most us ... concern, but a new study from the Osteoarthritis Initiative shows that certain ... knee osteoarthritis. Knowing this in advance may give doctors the opportunity to treat patients ...
(Date:5/26/2017)... ... May 26, 2017 , ... ... week to review more than eighty-nine grant submissions all vying for nearly $1,000,000 ... in the Parkinson’s field.     , The American Parkinson Disease Association (APDA) is focused ...
(Date:5/26/2017)... Fairfax, VA (PRWEB) , ... May 26, 2017 ... ... is pleased to announce a new educational seminar to focus on current legislative ... Regulatory News(LEARN) seminar will begin at 1 p.m. Sunday, Sept. 10, and will ...
(Date:5/26/2017)... ... May 26, 2017 , ... Somnoware, ... NOX-T3 portable sleep monitor with its Somnoware Sleep Device Interface (SDI). Somnoware SDI ... diagnostic device operations. With this platform, initializing devices and importing studies are just ...
(Date:5/26/2017)... ... May 26, 2017 , ... ... is sharing bold recipes for Memorial Day entertaining that are sure to satisfy ... “Boar’s Head fresh sliced meats and cheeses featured in these refreshingly balanced recipes ...
Breaking Medicine News(10 mins):
(Date:5/10/2017)... Radiology has become the number one diagnostic ... spiraled to the number one ranking as a result.  ... before as the most complete and reliable method for ... back pain an MRI may confirm a suspected herniated ... in entirely different treatment protocols.  In these circumstances, patients ...
(Date:5/9/2017)... , May 9, 2017  Demonstrating its ... board of directors for the Pharmaceutical Research and ... for membership. Biopharmaceutical companies will now have to ... order to be eligible to join PhRMA. ... the board is sending a clear message that ...
(Date:5/8/2017)... YORK , May 8, 2017 ... the transition from fee for service reimbursement. Black Book ... 2017. 1.       The Market for MIPS ... 77% of physician practices with 3 or more ... Technology Solutions by Q4. "Given the magnitude of the ...
Breaking Medicine Technology: